



S1 Fig. The study flowchart of patient selection. ECOG PS, Eastern Cooperative Oncology Group performance status; ICIs, immune checkpoint inhibitors; irAEs, immune-related adverse events; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1. ^a)Combination therapy includes PD-1/PD-L1 inhibitors monotherapy in combination with chemotherapy/antiangiogenic agents/other immune checkpoint inhibitors.